

Regeneron Pharmaceuticals Inc (REGN) - Financial and Strategic SWOT Analysis Review

URL:	https://marketpublishers.com/r/R8CF600A833EN.html
Date:	April 19, 2018
Pages:	61
Price:	US\$ 125.00
ID:	R8CF600A833EN

Regeneron Pharmaceuticals Inc (REGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Regeneron Pharmaceuticals Inc (Regeneron) is a biopharmaceutical company, which discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company's six US FDA-approved medicines and product candidates in development help patients with eye diseases, asthma, pain, cancer and heart, allergic, inflammatory and infectious diseases. It develops products based on its VelociSuite technology platforms, which include VelociGene, VelocImmune, VelociMouse, VelociMab and other related technologies. Regeneron also has various product candidates under clinical development for treating asthma, pain, cancer, atopic dermatitis and infectious diseases. It has subsidiaries in Belgium, Spain, Ireland, the Netherlands, the US and the UK. Regeneron is headquartered in Tarrytown, New York, the US.

Regeneron Pharmaceuticals Inc Key Recent Developments

Mar 21,2018: Regeneron Genetics Center Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease

Mar 13,2018: Teen Scientists Win \$1.8 Million at Regeneron Science Talent Search 2018 with Top Awards for Novel Research on Crop Blight, Vaping and Rare Disease

Feb 12,2018: Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial

Feb 08,2018: Regeneron Reports Fourth Quarter and Full Year 2017 Financial Results

Jan 08,2018: Regeneron Forms Consortium of Leading Life Sciences Companies to Accelerate Largest Widely-Available 'Big Data' Human Sequencing Resource with UK Biobank

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Content

SECTION 1 - ABOUT THE COMPANY

Regeneron Pharmaceuticals Inc - Key Facts

Regeneron Pharmaceuticals Inc - Key Employees

Regeneron Pharmaceuticals Inc - Key Employee Biographies

Regeneron Pharmaceuticals Inc - Major Products and Services

Regeneron Pharmaceuticals Inc - History

Regeneron Pharmaceuticals Inc - Company Statement
Regeneron Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Regeneron Pharmaceuticals Inc - Business Description
Product Category: Arcalyst
Overview
Performance
Product Category: Dupixent
Overview
Product Category: Eylea
Overview
Performance
Product Category: Kevzara
Overview
Product Category: Praluent
Overview
Product Category: Zaltrap
Overview
R&D Overview
Regeneron Pharmaceuticals Inc - Corporate Strategy
Regeneron Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Regeneron Pharmaceuticals Inc - Strengths
Regeneron Pharmaceuticals Inc - Weaknesses
Regeneron Pharmaceuticals Inc - Opportunities
Regeneron Pharmaceuticals Inc - Threats
Regeneron Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Regeneron Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Mar 21, 2018: Regeneron Genetics Center Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease
Mar 13, 2018: Teen Scientists Win \$1.8 Million at Regeneron Science Talent Search 2018 with Top Awards for Novel Research on Crop Blight, Vaping and Rare Disease
Feb 12, 2018: Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head

of Commercial

Jan 08, 2018: Regeneron Forms Consortium of Leading Life Sciences Companies to Accelerate Largest Widely-Available 'Big Data' Human Sequencing Resource with UK Biobank

Dec 27, 2017: Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron

Dec 27, 2017: Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron

Nov 08, 2017: Regeneron Reports Third Quarter 2017 Financial and Operating Results

Aug 03, 2017: Regeneron Reports Second Quarter 2017 Financial and Operating Results

Jul 28, 2017: U.S. Court of Appeals for the Federal Circuit Affirms Merus' Inequitable Conduct Claim Against Regeneron

Jun 21, 2017: Regeneron Recognized on "The Civic 50" List of the Most Community-Minded Companies in the United States

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

LIST OF TABLES

Regeneron Pharmaceuticals Inc, Key Facts

Regeneron Pharmaceuticals Inc, Key Employees

Regeneron Pharmaceuticals Inc, Key Employee Biographies

Regeneron Pharmaceuticals Inc, Major Products and Services

Regeneron Pharmaceuticals Inc, History

Regeneron Pharmaceuticals Inc, Other Locations

Regeneron Pharmaceuticals Inc, Subsidiaries

Regeneron Pharmaceuticals Inc, Key Competitors

Regeneron Pharmaceuticals Inc, Ratios based on current share price

Regeneron Pharmaceuticals Inc, Annual Ratios

Regeneron Pharmaceuticals Inc, Annual Ratios (Cont.1)

Regeneron Pharmaceuticals Inc, Annual Ratios (Cont.2)

Regeneron Pharmaceuticals Inc, Interim Ratios

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018

Regeneron Pharmaceuticals Inc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

LIST OF FIGURES

Regeneron Pharmaceuticals Inc, Performance Chart (2013 - 2017)

Regeneron Pharmaceuticals Inc, Ratio Charts

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Sanofi
Pfizer Inc
Novartis AG
Merck & Co Inc
Genentech Inc
Eli Lilly and Co
Bayer AG
Amgen Inc
Allergan Inc
Abbott Laboratories

I would like to order:

Product name: Regeneron Pharmaceuticals Inc (REGN) - Financial and Strategic SWOT Analysis Review
Product link: <https://marketpublishers.com/r/R8CF600A833EN.html>
Product ID: R8CF600A833EN
Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/R8CF600A833EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**